
Boehringer Ingelheim makes changes to board
pharmafile | July 5, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Boehringer Ingelheim
Boehringer Ingelheim has appointed Dr Joachim Hasenmaier to its board of managing directors.
The 52-year-old will take over responsibility for the new Consumer Health Care and Animal Health board division as of 1 October. Prior to his appointment, Hasenmaier was regional business manager for Northern Europe and Canada.
From 2001 to 2011, Hasenmaier was divisional head, Animal Health, at Boehringer Ingelheim. Before joining Boehringer, he held both management responsibilities in the field of animal health and worked as a consultant in Germany and internationally.
“Joachim Hasenmaier’s appointment is the outcome of a long-term human resource strategy. He has contributed to shaping the strategic and operational direction of our dynamically growing Animal Health business,” said Christian Boehringer, chairman of the shareholders’ committee at the firm.
Related Content

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio …

Brainomix and Boehringer Ingelheim enter strategic partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for …






